{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response, IRC assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"5"}]}],"title":"Partial Response, IRC assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"59"}]}],"title":"Stable Disease, IRC assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"58"}]}],"title":"Progressive Disease, IRC assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"23"}]}],"title":"Unknown, IRC assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"9"}]}],"title":"Partial Response, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"62"}]}],"title":"Stable Disease, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"65"}]}],"title":"Progressive Disease, Investigator assessed"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"}]}],"title":"Unknown, Investigator assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"Overall response is the number of participants who had a complete response (CR) or a partial response (PR). Per RECIST: CR, all detectable tumor has disappeared; PR, a \\>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the Baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a \\>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease, small changes that do not meet previously given criteria. IRC, independent review committee.","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Matching Placebo administered orally once a day","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Baseline until either response or progression (up to 2 years)","title":"Overall Response","type":"SECONDARY","unitOfMeasure":"participants"}